|
Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20 Clinical Trials
1 actively recruiting trial
Pipeline
Phase 1/2: 1
Top Sponsors
- Shenzhen Geno-Immune Medical Institute1
Indications
- CD19 Negative B-cell Malignancies1
- Cancer1
Other1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.